TVGN - NASDAQ

Tevogen Bio Holdings Inc.

TVGN·NASDAQ

$0.25

-5.8%

HealthcareBiotechnology

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$50.14M

EPS-0.0936

P/E Ratio-14.94

Earnings Date03/25/2026

tvgn

Cash at Beginning of Period

Last Annual Value

1.05M

3-Year CAGR

550%

5-Year CAGR

207%

10-Year CAGR

75%

Adjust for Inflation

Tevogen Bio Holdings Inc. Competitors Analysis of Cash at Beginning of Period

TVGN · NASDAQ

Company	Cash at Beginning of Period	CAGR 3Y	CAGR 5Y	CAGR 10Y
Tevogen Bio Holdings Inc. NASDAQ:TVGN	1.05M	-42.3%	207.3%	N/A
Whitehawk Therapeutics Inc NASDAQ:WHWK	28.67M	-9.8%	45.1%	N/A
Cognition Therapeutics, Inc. NASDAQ:CGTX	25.01M	-15.6%	37.0%	N/A
TuHURA Biosciences, Inc. NASDAQ:HURA	12.66M	-3.9%	20.1%	7.5%
Instil Bio, Inc. NASDAQ:TIL	10.63M	-37.6%	-46.5%	N/A
Surrozen, Inc. NASDAQ:SRZN	35.25M	12.0%	-0.1%	N/A
Greenwich LifeSciences, Inc. NASDAQ:GLSI	4.09M	-32.8%	-32.2%	N/A
Atossa Therapeutics, Inc. NASDAQ:ATOS	71.19M	-13.8%	12.4%	34.4%
Alto Neuroscience, Inc. NYSE:ANRO	168.73M	51.7%	111.3%	N/A
C4 Therapeutics, Inc. NASDAQ:CCCC	58.94M	21.3%	-20.4%	N/A
Nuvectis Pharma, Inc. NASDAQ:NVCT	18.53M	-2.5%	N/A	N/A

Tevogen Bio Holdings Inc. Fair Value Envelope

TVGN · NASDAQ

Our analysis suggests that TVGN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $0.2488, this represents a potential HIDDEN relative to our calculated worth for Tevogen Bio Holdings Inc..

HIDDEN

Intrinsic Value

Current Price: $0.2488

Related Guides

Blog Categories

Continue your TVGN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.